Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer

After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer. | After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer.

Raccontata dafiercepharma.com